EPO Patent Application: Mesothelin Binding Molecule

The European Patent Office has published patent application EP4269442A1 concerning a mesothelin binding molecule and its application. The application was filed by Zhejiang Nanomab Technology Center Co. Ltd. and lists multiple inventors. The publication date is March 11, 2026.

Patent EP4247855A1: Anti-CD73 Antibody, Drug Conjugate, and Use

The European Patent Office has published patent application EP4247855A1 concerning an anti-CD73 antibody, antibody-drug conjugate, and its therapeutic use. The patent was applied for by Bliss Biopharmaceutical (Hangzhou) Co., Ltd. and published on March 11, 2026.

Modified EGFR Antibody Drug Conjugate Patent Application

The European Patent Office has published a patent application (EP4247853A1) for a modified EGFR antibody drug conjugate developed by Bliss Biopharmaceutical (Hangzhou) Co., Ltd. The patent covers the antibody, the conjugate, and its use in treating diseases, particularly cancer. The publication date is March 11, 2026.

Anti-CD73 Antibody Patent Application Published

The European Patent Office has published patent application EP4234579A1 concerning an anti-CD73 antibody and its therapeutic uses. The application was filed by Akeso Biopharma, Inc. and Akeso Pharmaceuticals, Inc. and lists inventors LI, Baiyong, XIA, Yu, and WANG, Zhongmin.

EPO Patent Publication: Testosterone-Specific Affibody

The European Patent Office has published patent application EP4230651A1 concerning a testosterone-specific affibody and its uses, filed by Inssen Inc. This publication relates to potential new therapeutic or diagnostic applications in the pharmaceutical and biotechnology sectors.

EPO Patent Application EP4230656A1 - Anti-Trop-2 Antibody

The European Patent Office has published patent application EP4230656A1 concerning an anti-Trop-2 antibody and its medical use. The application was filed by Shanghai Hansoh Biomedical Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and is designated for several European states.

EPO Patent EP4333983A1: Mesothelin and Chimeric PD1 Receptor Molecules

The European Patent Office has published patent application EP4333983A1 concerning mesothelin isoform binding molecules and chimeric PD1 receptor molecules. The patent was filed by Immunocell Therapeutics, Inc. and lists specific inventors and IPC classifications.

Binder Molecules Affinity Specificity Patent Application

The European Patent Office has published patent application EP4271482A2, filed by Alamar Biosciences, Inc., concerning binder molecules with high affinity and/or specificity. The application details methods of making and using these molecules, with potential applications in disease treatment.

EPO Patent Application: C-Type Natriuretic Peptides for Cancer Treatment

The European Patent Office has published patent application EP4164672A2 concerning C-type natriuretic peptides and methods for treating cancer, filed by PharmaIN Corporation. The patent application details specific peptide compositions and their therapeutic applications.

EPO Patent Publication EP4175650A1: Mesothelin Binding Molecules

The European Patent Office (EPO) published patent application EP4175650A1 on March 11, 2026, concerning mesothelin isoform binding molecules and chimeric PD1 receptor molecules. The patent application was filed by Immunocell Therapeutics, Inc.